NO20073559L - Nanopartiklulaere tacrolimus-formuleringer - Google Patents
Nanopartiklulaere tacrolimus-formuleringerInfo
- Publication number
- NO20073559L NO20073559L NO20073559A NO20073559A NO20073559L NO 20073559 L NO20073559 L NO 20073559L NO 20073559 A NO20073559 A NO 20073559A NO 20073559 A NO20073559 A NO 20073559A NO 20073559 L NO20073559 L NO 20073559L
- Authority
- NO
- Norway
- Prior art keywords
- nanoparticulate tacrolimus
- tacrolimus formulations
- nanoparticulate
- formulations
- tacrolimus
- Prior art date
Links
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960001967 tacrolimus Drugs 0.000 title abstract 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63681704P | 2004-12-15 | 2004-12-15 | |
| US73186905P | 2005-11-01 | 2005-11-01 | |
| PCT/US2005/045540 WO2006066063A1 (en) | 2004-12-15 | 2005-12-15 | Nanoparticulate tacrolimus formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073559L true NO20073559L (no) | 2007-08-29 |
Family
ID=36190417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073559A NO20073559L (no) | 2004-12-15 | 2007-07-09 | Nanopartiklulaere tacrolimus-formuleringer |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20060159766A1 (pt) |
| EP (1) | EP1835889A1 (pt) |
| JP (1) | JP2008524239A (pt) |
| KR (1) | KR20070116581A (pt) |
| AU (1) | AU2005316473B2 (pt) |
| BR (1) | BRPI0519088A2 (pt) |
| CA (1) | CA2590675A1 (pt) |
| EA (1) | EA013741B1 (pt) |
| IL (1) | IL183945A0 (pt) |
| MX (1) | MX2007007342A (pt) |
| NO (1) | NO20073559L (pt) |
| SG (1) | SG161203A1 (pt) |
| WO (1) | WO2006066063A1 (pt) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2812185B1 (fr) | 2000-07-25 | 2003-02-28 | Spine Next Sa | Piece de liaison semi-rigide pour la stabilisation du rachis |
| US20060169199A1 (en) * | 2003-03-31 | 2006-08-03 | Vilmos Keri | Crystallization and purification of macrolides |
| ES2376238T3 (es) * | 2003-08-29 | 2012-03-12 | Veloxis Pharmaceuticals A/S | Composiciones de liberación modificada comprendiendo tacrolimus. |
| US7994214B2 (en) | 2003-08-29 | 2011-08-09 | Lifecycle Pharma A/S | Solid dispersions comprising tacrolimus |
| US20060210638A1 (en) * | 2005-03-17 | 2006-09-21 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
| CN101495096A (zh) | 2006-05-30 | 2009-07-29 | 伊兰制药国际有限公司 | 纳米微粒泊沙康唑制剂 |
| CA2657379A1 (en) * | 2006-07-10 | 2008-01-17 | Elan Pharma International Ltd. | Nanoparticulate sorafenib formulations |
| EP2071917B1 (en) * | 2006-09-29 | 2012-11-21 | Infa S.A. | Packaging system for pharmaceutical compositions and kit for intravenous administration |
| WO2008066899A2 (en) * | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
| EP1938800A1 (en) * | 2006-12-06 | 2008-07-02 | Ranbaxy Laboratories Limited | Sirolimus nanodispersion |
| JP2010515753A (ja) | 2007-01-10 | 2010-05-13 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 肺内送達用免疫抑制剤組成物の送達の増強 |
| AU2008288105A1 (en) * | 2007-03-29 | 2009-02-19 | Panacea Biotec Limited. | Modified dosage forms of tacrolimus |
| PL2167033T4 (pl) | 2007-05-30 | 2018-08-31 | Veloxis Pharmaceuticals A/S | Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus |
| US12083103B2 (en) | 2007-05-30 | 2024-09-10 | Veloxis Pharmaceuticals, Inc. | Tacrolimus for improved treatment of transplant patients |
| WO2009029543A1 (en) | 2007-08-24 | 2009-03-05 | Aegis Therapeutics, Llc | Controlled release formulations |
| HRP20191104T1 (hr) | 2007-09-25 | 2019-09-20 | Solubest Ltd. | Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu |
| WO2009073215A1 (en) * | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
| CL2008000374A1 (es) | 2008-02-05 | 2008-04-04 | Igloo Zone Chile S A | Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve |
| EP2268265A2 (en) * | 2008-03-21 | 2011-01-05 | Elan Pharma International Limited | Compositions for site-specific delivery of imatinib and methods of use |
| US12403095B2 (en) | 2008-05-30 | 2025-09-02 | Veloxis Pharmaceuticals, Inc. | Stabilized tacrolimus composition |
| US20110165259A1 (en) | 2008-09-19 | 2011-07-07 | Activus Pharma Co., Ltd. | Composite organic compound powder for medical use, method for producing same and suspension of same |
| CA2937492C (en) * | 2008-11-11 | 2019-08-13 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
| WO2010118232A1 (en) * | 2009-04-09 | 2010-10-14 | Elan Pharma International Limited | Controlled-release clozapine compositions |
| CA2759123C (en) | 2009-04-24 | 2019-01-15 | Iceutica Pty Ltd | Compositions of diclofenac acid with improved dissolution |
| JP6072539B2 (ja) | 2009-05-27 | 2017-02-01 | アルカーメス ファーマ アイルランド リミテッド | ナノ粒子活性物質組成物におけるフレーク状凝集の軽減 |
| US8778364B2 (en) * | 2009-06-19 | 2014-07-15 | Sun Pharma Advanced Research Company Ltd. | Nanodispersion of a drug and process for its preparation |
| WO2015161139A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
| ES2591352T3 (es) | 2010-02-17 | 2016-11-28 | Veloxis Pharmaceuticals A/S | Composición de tacrolimus estabilizada |
| WO2012026896A1 (en) * | 2010-08-25 | 2012-03-01 | Les Laboratoires Medis Sa | Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof |
| CN107320734A (zh) | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| JP6382187B2 (ja) | 2012-06-21 | 2018-08-29 | フォスフォレックス,インコーポレーテッド | インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法 |
| EA032913B1 (ru) * | 2012-10-18 | 2019-08-30 | Эббви Инк. | Препараты производных пиримидиндиона |
| CA2903433A1 (en) * | 2013-03-04 | 2014-09-12 | Vtv Therapeutics Llc | Stable glucokinase activator compositions |
| US20160030401A1 (en) | 2013-03-13 | 2016-02-04 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of intestinal polyp growth and cancer |
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| EP4599848A3 (en) | 2017-03-11 | 2025-12-03 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| CA3063417C (en) | 2018-12-04 | 2023-01-03 | Leon-Nanodrugs Gmbh | Nanoparticles comprising tacrolimus |
| TWI764159B (zh) | 2019-05-31 | 2022-05-11 | 財團法人醫藥工業技術發展中心 | 口服組合物、製造方法及其用途 |
| US12553041B2 (en) | 2019-06-04 | 2026-02-17 | Cartesian Therapeutics Inc. | Formulations and doses of pegylated uricase |
| EP4014963A1 (en) | 2020-12-16 | 2022-06-22 | Medincell | Pharmaceutical composition |
| EP4628891A1 (en) * | 2022-11-29 | 2025-10-08 | Jichi Medical University | Method for quantifying analyte containing mycophenolic acid and one or more other immunosuppressants in target blood sample |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| US4783484A (en) * | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US5194378A (en) * | 1991-01-28 | 1993-03-16 | Merck & Co., Inc. | Process for producing fk-506 |
| AU2317592A (en) * | 1991-07-05 | 1993-02-11 | University Of Rochester | Ultrasmall non-aggregated porous particles entrapping gas-bubbles |
| NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| US5349957A (en) * | 1992-12-02 | 1994-09-27 | Sterling Winthrop Inc. | Preparation and magnetic properties of very small magnetite-dextran particles |
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) * | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
| US5401492A (en) * | 1992-12-17 | 1995-03-28 | Sterling Winthrop, Inc. | Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5264610A (en) * | 1993-03-29 | 1993-11-23 | Sterling Winthrop Inc. | Iodinated aromatic propanedioates |
| TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US5718388A (en) * | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
| US5525328A (en) * | 1994-06-24 | 1996-06-11 | Nanosystems L.L.C. | Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging |
| US5587143A (en) * | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5466440A (en) * | 1994-12-30 | 1995-11-14 | Eastman Kodak Company | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays |
| US5628981A (en) * | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
| US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5662883A (en) * | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5665331A (en) * | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5569448A (en) * | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5560931A (en) * | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5593657A (en) * | 1995-02-09 | 1997-01-14 | Nanosystems L.L.C. | Barium salt formulations stabilized by non-ionic and anionic stabilizers |
| US5500204A (en) * | 1995-02-10 | 1996-03-19 | Eastman Kodak Company | Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging |
| US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5543133A (en) * | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
| US5580579A (en) * | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5565188A (en) * | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| AU4990696A (en) * | 1995-02-24 | 1996-09-11 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
| US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5573749A (en) * | 1995-03-09 | 1996-11-12 | Nano Systems L.L.C. | Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
| US5643552A (en) * | 1995-03-09 | 1997-07-01 | Nanosystems L.L.C. | Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging |
| US5472683A (en) * | 1995-03-09 | 1995-12-05 | Eastman Kodak Company | Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging |
| US5521218A (en) * | 1995-05-15 | 1996-05-28 | Nanosystems L.L.C. | Nanoparticulate iodipamide derivatives for use as x-ray contrast agents |
| US5573750A (en) * | 1995-05-22 | 1996-11-12 | Nanosystems L.L.C. | Diagnostic imaging x-ray contrast agents |
| US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| ES2306452T3 (es) * | 1995-10-17 | 2008-11-01 | Jagotec Ag | Aporte de farmacos insolubles. |
| US6458811B1 (en) * | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
| WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| US6153225A (en) * | 1998-08-13 | 2000-11-28 | Elan Pharma International Limited | Injectable formulations of nanoparticulate naproxen |
| US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
| US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
| IL142896A0 (en) * | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
| US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| CA2393195C (en) * | 1999-06-01 | 2007-02-20 | Elan Pharma International Limited | Small-scale mill and method thereof |
| US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| ATE453454T1 (de) * | 2000-04-26 | 2010-01-15 | Elan Pharma Int Ltd | Vorrichtung zur sanitären nassvermahlung |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| NZ526608A (en) * | 2000-12-22 | 2006-06-30 | Baxter Int | Method for preparing submicron particle suspensions |
| US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
| EP1392441B1 (en) * | 2001-06-05 | 2008-07-23 | Elan Pharma International Limited | System and method for milling materials |
| JP2005508939A (ja) * | 2001-10-12 | 2005-04-07 | エラン ファーマ インターナショナル,リミティド | 即時放出および徐放特性を組み合わせて有する組成物 |
| US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| AU2003241478A1 (en) * | 2002-06-10 | 2003-12-22 | Elan Pharma International, Ltd. | Nanoparticulate sterol formulations and sterol combinations |
| EP1511467A1 (en) * | 2002-06-10 | 2005-03-09 | Elan Pharma International Limited | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
| EP2283864A1 (en) * | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Liquid dosage compositions fo stable nanoparticulate active agents |
| CA2500908A1 (en) * | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| US20040173696A1 (en) * | 2002-12-17 | 2004-09-09 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
| AU2004240640A1 (en) * | 2003-05-19 | 2004-12-02 | Baxter International Inc. | Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers |
| US20060210638A1 (en) * | 2005-03-17 | 2006-09-21 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
-
2005
- 2005-12-15 JP JP2007546924A patent/JP2008524239A/ja active Pending
- 2005-12-15 EP EP05854300A patent/EP1835889A1/en not_active Withdrawn
- 2005-12-15 AU AU2005316473A patent/AU2005316473B2/en not_active Ceased
- 2005-12-15 BR BRPI0519088-6A patent/BRPI0519088A2/pt not_active IP Right Cessation
- 2005-12-15 KR KR1020077015992A patent/KR20070116581A/ko not_active Ceased
- 2005-12-15 US US11/300,592 patent/US20060159766A1/en not_active Abandoned
- 2005-12-15 SG SG201001728-3A patent/SG161203A1/en unknown
- 2005-12-15 MX MX2007007342A patent/MX2007007342A/es not_active Application Discontinuation
- 2005-12-15 WO PCT/US2005/045540 patent/WO2006066063A1/en not_active Ceased
- 2005-12-15 CA CA002590675A patent/CA2590675A1/en not_active Abandoned
- 2005-12-15 EA EA200701274A patent/EA013741B1/ru not_active IP Right Cessation
-
2007
- 2007-06-14 IL IL183945A patent/IL183945A0/en unknown
- 2007-07-09 NO NO20073559A patent/NO20073559L/no not_active Application Discontinuation
-
2008
- 2008-02-27 US US12/071,849 patent/US20080152720A1/en not_active Abandoned
-
2009
- 2009-06-12 US US12/484,073 patent/US20090252806A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080152720A1 (en) | 2008-06-26 |
| MX2007007342A (es) | 2007-12-11 |
| AU2005316473A1 (en) | 2006-06-22 |
| US20090252806A1 (en) | 2009-10-08 |
| IL183945A0 (en) | 2007-10-31 |
| AU2005316473B2 (en) | 2011-07-14 |
| EA200701274A1 (ru) | 2007-12-28 |
| EA013741B1 (ru) | 2010-06-30 |
| SG161203A1 (en) | 2010-05-27 |
| US20060159766A1 (en) | 2006-07-20 |
| BRPI0519088A2 (pt) | 2008-12-23 |
| JP2008524239A (ja) | 2008-07-10 |
| WO2006066063A1 (en) | 2006-06-22 |
| CA2590675A1 (en) | 2006-06-22 |
| EP1835889A1 (en) | 2007-09-26 |
| KR20070116581A (ko) | 2007-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200701274A1 (ru) | Нанодисперсные составы на основе такролимуса | |
| NO20073780L (no) | Nanopartikulaere kandesartan-formuleringer | |
| DE602004021107D1 (de) | Meloxican-formulierungen in nanoteilchenform | |
| WO2007064912A3 (en) | Mometasone compositions and methods of making and using the same | |
| EA200702638A1 (ru) | Стабильная композиция (рецептура) с наночастицами ацетаминофена | |
| NO20073334L (no) | Nanopartikulaert benzotiofenformuleringer | |
| EA200701997A1 (ru) | Композиция из наночастиц бисфосфоната | |
| ATE387186T1 (de) | Neue zusammensetzungen von sildenafil-freier base | |
| DE602004018150D1 (de) | Neue metaxalon-zusammensetzungen | |
| AU2002367315A1 (en) | Sterile filtered nanoparticule formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer | |
| DE60332212D1 (de) | Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator | |
| SG170047A1 (en) | Nanoparticulate posaconazole formulations | |
| WO2010138539A3 (en) | Reduction of flake-like aggregation in nanoparticulate active agent compositions | |
| TW200613479A (en) | Coating formulation having improved rheological properties | |
| WO2006091780A3 (en) | Nanoparticulate formulations of docetaxel and analogues thereof | |
| CY1113036T1 (el) | Φαρμακοτεχνικες μορφες νανοσωματιδιων μεγεστρολης | |
| DE60309300D1 (de) | Nanopartikelzusammensetzungen von angiogeneseinhibitoren | |
| MX2010009866A (es) | Composiciones de inhibidores de angiogenesis en nanoparticulas. | |
| MA28999B1 (fr) | Compositions destinees a lutter contre un ou plusieurs pathogenes | |
| NO20080403L (no) | Nanopartikulaere megestrolformuleringer | |
| WO2010084398A3 (en) | Mouth rinse compositions including chemically modified silica or silicate materials for sustained delivery to tooth surfaces | |
| WO2008073982A3 (en) | 5,6-dihydro-1h-pyridin-2-one compounds | |
| WO2008132021A3 (de) | Fungizide mischungen | |
| TW200636025A (en) | Light stabilizer emulsion composition | |
| WO2007067519A3 (en) | The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |